Introduction {#sec1}
============

All amino acids except glycine have two enantiomers: [l]{.smallcaps}-amino acid and [d]{.smallcaps}-amino acid. [l]{.smallcaps}-Amino acid has been assumed to be an exclusive constituent of proteins in nature. However, recent studies have demonstrated the presence of many [d]{.smallcaps}-amino acid-containing proteins in various aged tissues, such as eye lens, brain, and skin.^[@ref1]−[@ref5]^ Above all, the [d]{.smallcaps}-aspartic acid (Asp) residue is considered to be associated with age-related disorders because many [d]{.smallcaps}-Asp residues have been found to accumulate in aged proteins as compared with other amino acid residues. Commonly, Asp residues in proteins are of the [l]{.smallcaps}α form; however, [l]{.smallcaps}α-Asp residues in proteins can be nonenzymatically isomerized to abnormal [l]{.smallcaps}β-, [d]{.smallcaps}α-, and [d]{.smallcaps}β-Asp isomers under physiological conditions via the formation of a succinimidyl intermediate over time, as shown in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}([@ref6]) Isomerization of Asp is considered to be a trigger of protein denaturation as it induces elongation of the main chain and a different orientation of the side chain within the protein structure.

![Isomerization pathways of aspartic acid via succinimidyl intermediates.](ao-2016-00346d_0008){#fig1}

Aki et al. studied the kinetics of isomerization of Asp residues in peptides, predicting that \>60% of [l]{.smallcaps}α-Asp will isomerize to the [l]{.smallcaps}β-Asp form within a few years in metabolically inert tissues.^[@ref7]^ Therefore, isomerization of Asp residues is considered to be related to not only age-related disorders but also a wide range of protein-degenerative diseases, such as prion diseases. An analysis of changes in protein function due to isomerization of Asp is thus required.

Protein expression using recombinant DNA technology is the principal method of producing a target protein. Although it is the most frequently used approach, it is unable to produce [d]{.smallcaps}-Asp-containing proteins because this Asp isomer is a noncoded amino acid. In addition, although chemical synthesis is able to introduce Asp isomers into a peptide chain, the synthesis of a large polypeptide with more than 50 amino acid residues is technically difficult. It is also very difficult to extract the [d]{.smallcaps}-Asp-containing protein from aged tissue because of the very small amounts of these proteins. Given the above background, methods for the preparation of Asp isomer-containing protein are limited. Here, to overcome these limitations, we have focused on a combination of native chemical ligation (NCL) and chemical peptide synthesis to create an Asp-isomer-containing protein and evaluated the effect of Asp isomerization on this protein.

NCL, a coupling reaction that produces an amide bond between the thiol of an N-terminal cysteine (Cys) residue in one peptide and a C-terminal thioester in another peptide, was developed by Dawson et al.,^[@ref8]^ which can be combined with expressed protein ligation (EPL), where the C-terminal thioester is produced by recombinant DNA technology. On the basis of these ligation reactions, several proteins have been synthesized.^[@ref9]−[@ref13]^ However, EPL is restricted to the synthesis of proteins containing Asp isomers because the cysteine residue must be located near the N- or C-terminus and the isomerization site of the Asp residue needs to be located outside this cysteine. Therefore, as an initial step to clarify the effect of Asp isomerization on protein function, we carried out a study on bovine pancreatic ribonuclease A (RNase A, EC 3.1.27.5), which has a native Asp residue that is amenable to EPL.

RNase A is a small monomeric protein composed of 124 amino acids with a molecular mass of 13 690. The three-dimensional structure of RNase A is fully defined by its amino acid sequence.^[@ref14],[@ref15]^ Therefore, RNase A has been used extensively as a model protein to clarify structure--activity relationships, as summarized by Raines.^[@ref16]^ The active site of RNase A has been clearly defined: two histidine (His12 and His119) and one lysine (Lys41) are the most important amino acids for the activity of RNase A. Structural analyses show that Asp121 forms a hydrogen bond with His119 during RNA cleavage by RNase A.^[@ref17],[@ref18]^ In a site-directed mutagenesis study, where Asp121 was replaced by a glutamate residue (D121E), the catalytic activity of D121E decreased to 17% compared to that of wild-type RNase A. Furthermore, Asp121 is located near the C-terminus, and Cys110 is located on the inside of Asp121^[@ref19]^ ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). Hence, Asp121 of RNase A is well positioned for isomer replacement via EPL.

![Structure of bovine pancreas ribonuclease A (EC3.1.27.5). The positions of Asp121 and Cys110 are shown in red and blue, respectively.](ao-2016-00346d_0003){#fig2}

In this study, Asp121 of RNase A was replaced by three abnormal Asp isomers using EPL. The large segment of RNase A (residues 1--109) with a C-terminal thioester was expressed by the recombinant DNA technology. The short segment of RNase A corresponding to residues 110--124 with an N-terminal Cys residue was synthesized by the solid-phase peptide synthesis method, in which Asp121 was replaced by each of the Asp isomers. After their preparation, the large segment of RNase A was ligated to the short segment containing [l]{.smallcaps}α-Asp, [l]{.smallcaps}β-Asp, [d]{.smallcaps}α-Asp, or [d]{.smallcaps}β-Asp to form [l]{.smallcaps}α-RNase A, [l]{.smallcaps}β-RNase A, [d]{.smallcaps}α-RNase A, and [d]{.smallcaps}β-RNase A, respectively ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). The catalytic activities of different Asp-isomer-containing RNase A enzymes were then compared.

![Overview of the synthesis of RNase A by EPL.](ao-2016-00346d_0004){#fig3}

In the present study, we report the novel preparation of a protein with each Asp isomer incorporated at a specific site coupled with an investigation of the function of the resultant variant proteins. The results clearly show that Asp isomerization affects the protein function.

Results {#sec2}
=======

Synthesis of Asp-Isomer-Containing RNase A by EPL {#sec2.1}
-------------------------------------------------

In this study, we synthesized an Asp-isomer-containing RNase A using EPL. The progression of the ligation reaction between the large segment and the short segment was monitored by sodium dodecyl sulfate-polyacrylamide gel electrophoresis using 15% polyacrylamide gels. [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"} shows the electrophoretogram of the large segment of RNase A (1--109) (lane 2), after the cleavage of intein (lane 3), and after the ligation of the short segment of RNase A (110--124) containing [l]{.smallcaps}α-, [l]{.smallcaps}β-, [d]{.smallcaps}α-, and [d]{.smallcaps}β-Asp at position 121 in lanes 4--7, respectively. Lane 3 indicates that intein was cleaved by 2-mercaptoethane sulfonate (MESNA) from RNase A (1--109), whereas lanes 4--7 indicate that the short segment of RNase A (110--124) was connected to the large segment of RNase A (1--109). The ligation efficiency did not differ among the different types of Asp isomer. After ligation, the His-tag was removed from RNase A (1--124) using factor Xa. About 50% of the His-tag was removed from [l]{.smallcaps}α-RNase A over a reaction time of 20 h ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}a). [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}b shows the four isomeric RNases after removal of the His-tag by factor Xa. The four RNases, which still contained His-tag, were purified by ion-exchange chromatography using a cation-exchange column (TOYOPERL CM-650M; Tosoh Bioscience, Japan) ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}). [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"} clearly shows the purity of the four RNases after ion-exchange chromatography.

![Electrophoretogram of the expressed intein-fused RNase A before and after peptide ligation using 15% polyacrylamide gel.](ao-2016-00346d_0005){#fig4}

![Electrophoretogram of RNase A (1--124) before and after removal of the His-tag by factor Xa using 15% polyacrylamide gels. (a) Time course of the His-tag removal reaction from [l]{.smallcaps}α-RNase A by factor Xa. (b) Comparison of the molecular weights of four isomeric RNases after removal of the His-tag using factor Xa for 20 h.](ao-2016-00346d_0006){#fig5}

![Elution profiles of ion-exchange chromatography using a cation-exchange column (CM-650M) with a linear gradient of 0--1 M NaCl in the presence of 20 mM Tris--HCl (pH 7.4) at a flow rate of 1 mL/min and electrophoretograms of purified Asp-isomer-containing RNase A (1--124) using 15% polyacrylamide gel; (a) [l]{.smallcaps}α-RNase, (b) [l]{.smallcaps}β-RNase A, (c) [d]{.smallcaps}α-RNase A, and (d) [d]{.smallcaps}β-RNase A.](ao-2016-00346d_0007){#fig6}

Differential RNase Activity Depending on Asp Isomerization {#sec2.2}
----------------------------------------------------------

The catalytic activity of RNase A toward 2′,3′-cCMP was measured by monitoring the increase in absorbance at 284 nm. [Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"} shows the time course of the activity of the RNase A variants with different Asp isomers. The catalytic activity of [l]{.smallcaps}α-RNase A was at the same level as that of commercially available RNase A (Sigma-Aldrich, St. Louis, MO). On the other hand, replacement of the [l]{.smallcaps}α-Asp isomer at position 121 with [l]{.smallcaps}β-, [d]{.smallcaps}α-, and [d]{.smallcaps}β-Asp decreased the RNase activity.

![Comparison of the catalytic activities of four RNase A proteins containing different Asp isomers.](ao-2016-00346d_0001){#fig7}

Differential RNase Solubility Depending on Asp Isomerization {#sec2.3}
------------------------------------------------------------

The solubility of RNase A differed depending on the type of replacement of the Asp isomer. An aliquot of the RNase A (1--124) enzymes containing Asp isomers was stored in a lyophilized state after dialysis against water. Lyophilized RNase A containing [l]{.smallcaps}α-Asp and [d]{.smallcaps}α-Asp was soluble in water at a final concentration of 1 mg/mL. By contrast, RNase A containing [l]{.smallcaps}β-Asp and [d]{.smallcaps}β-Asp showed a very low solubility in water.

Discussion {#sec3}
==========

In this study, a protein containing four different Asp isomers was initially synthesized, and it was revealed for the first time that isomerization of an Asp residue in the protein induced a marked change in protein function and solubility. RNase A was selected as an initial model protein to introduce four different Asp isomers because (1) it is amenable to EPL and (2) it is easy to evaluate the changes in RNase A function caused by Asp isomerization.

Our results clearly indicated that the catalytic activity of RNase A was completely lost by introducing abnormal Asp isomers at position 121. The loss of activity of the isomeric RNase A enzymes might be due to the structural changes caused by introducing isomerization at Asp121. We tried to analyze the structures of these proteins using X-ray crystallography, nuclear magnetic resonance analysis, circular dichroism spectroscopy, and infrared spectroscopy. However, structural information could not be obtained because of the low solubility of the isomeric RNase A proteins. In a previous study, the RNase activity of a D121E variant was found to decrease by approximately 83%.^[@ref20]^ In common with gene mutation, the introduction of Asp isomers at position 121 clearly had a large effect on enzyme activity.

His12, His119, and Lys41 are the most important amino acids for the activity of RNase A. Asp121 forms a hydrogen bond with His119 during the RNA cleavage by RNase A. It is likely that the isomerization of Asp121 made it impossible for His119 to form the hydrogen bond that is needed for RNase activity. In addition to this functional change, the Asp isomerization affected the solubility of RNase A. Although Asp121 of RNase A is not isomerized in vivo, this study provides valuable information on the functional changes that are likely to occur in a protein due to the replacement of a single Asp isomer.

Asp isomers are often found in various metabolically inert tissues, such as eye lens, brain, skin, bone, artery wall, and tooth.^[@ref1]−[@ref5]^ In particular, they are found in metabolically inert proteins, such as crystallin from eye lens and β-amyloid protein from brain.^[@ref21]−[@ref27]^

In 2006, Fujii et al. demonstrated that the isomerization of one Asp residue in a partial peptide of αB-crystallin induced changes in the secondary structure, hydrophobicity, and chaperone activity.^[@ref28]^ Molecular dynamics simulation also revealed that the inversion of [l]{.smallcaps}-leucine to [d]{.smallcaps}-leucine at position 2 in the tetrapeptide Leu-Leu-Gly-Asp induced a change in its three-dimensional structure.^[@ref29]^ These structural changes may be a trigger of protein dysfunction and insolubilization. Indeed, our previous study supported the hypothesis that αB-crystallin and βA3-crystallin, in which an Asp residue is inverted from the [l]{.smallcaps}-form to the [d]{.smallcaps}-form, cannot assemble the crystallin complex in aged human lens.^[@ref30]^ In addition, a large amount of Asp isomers has been found in the insoluble fraction of human cataract lens compared to that of the soluble fraction.^[@ref31]^

In addition, it has been reported that, apart from isomerization, various amino acid modifications, such as deamidation, truncation, oxidation, and methylation, occur in human crystallin. These modifications are also considered to be a factor in the insolubilization of human lens.^[@ref32]−[@ref38]^

Asp isomers tend to accumulate in a metabolically inert tissue, such as crystallin, because the isomerization of Asp undergoes an equilibrium reaction. Therefore, the accumulation of proteins, in which function and solubility are decreased by the isomerization of Asp, may be a trigger of age-related diseases. It is considered that the dysfunction of RNase A observed in this study is also related to the denaturation of this enzyme. In terms of RNase A, isomerization from the α-form to the β-form (epimerization) may induce larger changes in the protein structure compared to those by the isomerization from the [l]{.smallcaps}-form to the [d]{.smallcaps}-form (inversion) because lyophilized RNase A containing β-Asp ([l]{.smallcaps}β- and [d]{.smallcaps}β-Asp) was insoluble, whereas RNase A containing [d]{.smallcaps}α-Asp remained soluble. Asp121 of RNase A is located near the C-terminus and forms a β-sheet structure through hydrogen bonds between NH and CO groups in the main chain of the protein. Because epimerization of an Asp residue extends the main chain of the protein, the β-sheet structure would be broken in RNase A containing [l]{.smallcaps}β- and [d]{.smallcaps}β-Asp. On the other hand, the overall structure might not be affected in RNase A containing [d]{.smallcaps}α-Asp. However, side-chain orientation is also important for RNase activity because the carboxylic group of Asp121 is related to the stabilization of the active center of RNase A. Thus, the inversion of Asp121 is considered to affect the stabilization of the active-site structure in RNase A. In this study, the Asp-isomer-containing RNase A proteins showed decreased solubility, suggesting that their structures might differ from those of [l]{.smallcaps}α-RNase A. [l]{.smallcaps}α-RNase A was undoubtedly folded to the proper structure because its enzymatic activity was the same as that of commercially available RNase A. This result suggested that protein disulfide isomerase (PDI) properly folded the chemically synthesized RNase A enzymes. On the one hand, PDI has the ability to refold not only RNase A but also other proteins by replacing non-native disulfides with the correct native ones.^[@ref39]−[@ref41]^ On the other hand, the enzymatic activity of the isomeric RNases was decreased despite using PDI. Therefore, isomerization of Asp121 in RNase A is considered to affect the RNase activity. Even if the isomeric RNases were misfolded, PDI might not refold them properly because it might not recognize a protein containing an Asp isomer. Nevertheless, although we could not determine the structure of the isomeric RNases, Asp isomerization undoubtedly changed the behavior of RNase. The selection of a suitable protein for analyzing the structural changes induced by the isomerization may help us to solve this problem. However, the isomerization of Asp is considered to be strongly related to protein aggregation, as observed for crystallin and β-amyloid protein. Therefore, it might be difficult to analyze the structural changes caused by the isomerization of Asp by avoiding aggregation of the protein.

This study demonstrated that EPL is a useful method to construct Asp-isomer-containing proteins. Synthesis of various proteins containing Asp isomer using EPL would be an effective way to verify the relationship between protein aggregation and isomerization of Asp.

Isomerization of Asp is one of the many post-translational modifications of proteins, including acetylation, phosphorylation, glycation, and deamidation. Asp isomers in aged proteins are produced spontaneously and slowly over time during the life span of an animal. Most cases of cataract and Alzheimer's disease develop during the aging process regardless of the presence or absence of a genetic defect. Indeed, a large amount of Asp isomers are found in patients with these diseases. Therefore, it is strongly suspected that Asp isomerization is related to the aggregation and malfunction of aged proteins. Asp isomerization will be an important factor in age-related diseases even if an individual is born healthy. To clarify the effect of different Asp isomers on a protein, it is necessary to synthesize proteins containing each of the four Asp isomers. To date, however, limitations in the methods of protein synthesis have prevented the widespread use of this approach. For example, recombinant DNA technology cannot introduce Asp isomers into a protein, as the standard solid-phase peptide synthesis cannot prepare polypeptides longer than 100 amino acids. Therefore, EPL was used to overcome these problems in the present study. However, other approaches will be necessary to find further information about functional changes caused by Asp isomerization. For example, the isomerization site of Asp in crystallin in vivo is located on the inner side of crystallin. Thus, the synthesis of Asp-isomer-containing crystallin protein using EPL would be difficult because the site of the Asp isomer must be located near the N- or C-terminus and the cysteine residue required for EPL needs to be located inside the site of the Asp isomer. Thus, a method other than EPL is needed to synthesize crystallins containing Asp isomers. Human secretory phospholipase A2 has been synthesized by NCL,^[@ref42]^ which might be applicable to crystallins and other proteins containing Asp isomers. The synthesis of crystallins and other proteins containing Asp isomers is a subject for our future studies.

In summary, it has been clarified that the introduction of Asp isomers into a protein decreases the protein function and leads to insolubilization. Exploring the role of [d]{.smallcaps}-amino acids in proteins in an [l]{.smallcaps}-amino acid world opens up a new field of protein science and will be useful to understand the mechanism underlying the onset of age-related diseases.

Experimental Procedures {#sec4}
=======================

Peptide Synthesis {#sec4.1}
-----------------

The short segment of RNase A (residues 110--124; Cys-Gln-Gly-Asn-Pro-Tyr-Val-Pro-Val-His-Phe-Asp121-Ala-Ser-Val), containing four different Asp isomers at Asp121, was synthesized by 9-fluorenylmethyloxycarbonyl group (Fmoc)-based solid-phase peptide synthesis using an automated solid-phase peptide synthesizer (PSSM-8; Shimadzu, Japan). Fmoc amino acids and other coupling reagents were purchased from Watanabe Chemical Industries, Ltd. Fmoc-[l]{.smallcaps}-Asp(OtBu)-OH for use as [l]{.smallcaps}α-Asp was converted to Fmoc-[l]{.smallcaps}-Asp-OtBu-OH, Fmoc-[d]{.smallcaps}-Asp(OtBu)-OH, and Fmoc-[d]{.smallcaps}-Asp-OtBu-OH for use, respectively, as [l]{.smallcaps}β-, [d]{.smallcaps}α-, and [d]{.smallcaps}β-Asp. The coupling reaction was carried out by mixing each Fmoc amino acid (10 equiv), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (10 equiv), 1-hydroxybenzotriazole hydrate (10 equiv), and *N*-methylmorpholine (7.5 equiv) in *N*,*N*-dimethylformamide (DMF). The N-terminal Fmoc group was deblocked with 30% piperidine in DMF. A spontaneous cleavage of the peptide from the resin and the removal of the protective groups were achieved by the treatment of a mixture containing 90% trifluoroacetic acid (TFA), 5% 1,2-ethanedithiol, and 5% thioanisole for 2 h. The crude peptides were purified by reversed-phase high-performance liquid chromatography using a C18 column (Capcell Pak C18 ACR, 10 × 250 mm^2^; Shiseido, Japan) with a linear gradient of 0--50% acetonitrile in the presence of 0.1% TFA at a flow rate of 3.0 mL/min and detection at 230 nm.

Construction of Expression Plasmid Containing the Intein-Fused RNase A Gene {#sec4.2}
---------------------------------------------------------------------------

A complementary DNA (cDNA) of RNase A was purchased from Open Biosystems, Inc. Site-directed mutagenesis was carried out to delete the *Sap*I restriction site in the RNase A gene. After mutagenesis, the cDNA of RNase A encoding amino acids 1--109 was amplified by polymerase chain reaction (PCR). During the PCR, an *Nde*I restriction site, His-tag, and factor Xa site were incorporated at the 5′ end, and an *Sap*I restriction site was added at the 3′ end of the RNase A gene (1--109) ([Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.6b00346/suppl_file/ao6b00346_si_001.pdf)). The amplified gene was cloned into a pTXB1 vector using *Nde*I and *Sap*I. The primers used in the mutagenesis and PCR are given in [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.6b00346/suppl_file/ao6b00346_si_001.pdf).

Expression of the Intein Fusion Protein {#sec4.3}
---------------------------------------

The constructed plasmid was transformed into T7 express lysY/Iq Competent *Escherichia coli* (New England BioLabs, Ipswich, MA), and a large segment of RNase A (1--109) was expressed. The crude extract was purified by affinity chromatography using a Ni-sepharose column (HisPrep FF 16/10 Column; GE Healthcare UK Ltd) with a linear gradient of 0--250 mM imidazole in the presence of 20 mM Tris--HCl (pH 7.4), 500 mM NaCl, and 2 M urea at a flow rate of 1 mL/min using an AKTAprime system (GE Healthcare Life Sciences) ([Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.6b00346/suppl_file/ao6b00346_si_001.pdf)).

EPL {#sec4.4}
---

The purified large segment of RNase A (1--109) dissolved in 20 mM Tris--HCl (pH 7.4), 500 mM NaCl, and 2 M urea was treated with MESNA for 20 h to cleave intein ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B). After cleavage, the short segment of RNase A (110--124) was added to the RNase A (1--109) solution ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C). The resulting RNase A (1--124) fused to His-tag was purified by affinity chromatography using a Ni-sepharose column (HisPrep FF 16/10 Column; GE Healthcare UK Ltd). After purification, the RNase A was treated by factor Xa (Merck Millipore, Darmstadt, Germany) in 50 mM Tris--HCl (pH 8.0), 100 mM NaCl, and 5 mM CaCl~2~ to cleave the His-tag ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}D). The full-length RNase A was purified by ion-exchange chromatography using a cation-exchange column (TOYOPERL CM-650M; Tosoh Bioscience, Japan) with a linear gradient of 0--1 M NaCl in the presence of 20 mM Tris--HCl (pH 7.4) at a flow rate of 1 mL/min using an AKTAprime system ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}).

Assay of RNA Cleavage Activity {#sec4.5}
------------------------------

The activity of RNase A was measured as described by Crook et al.^[@ref43]^ In this study, 12 μg of RNase A was refolded using PDI (Takara Bio, Japan) in the presence of 20 mM reduced [l]{.smallcaps}-glutathione and 2 mM oxidized [l]{.smallcaps}-glutathione for 1 min at 25 °C. After refolding, the RNase A was added to 0.1 M cytidine 2′:3′-cyclic monophosphate (2′,3′-cCMP, Sigma-Aldrich, St. Louis, MO) dissolved in 0.1 M MOPS buffer (pH 7.0). The rate of increase in the absorbance at 284 nm was monitored by absorption spectrophotometry (UV-2700; Shimadzu, Japan).

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.6b00346](http://pubs.acs.org/doi/abs/10.1021/acsomega.6b00346).Detailed description of the general experimental procedures, including the purification data of Asp isomers containing RNase A, is provided ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.6b00346/suppl_file/ao6b00346_si_001.pdf))
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2′,3′-cCMP

:   cytidine 2′:3′-cyclic monophosphate

cDNA

:   complementary DNA

DMF

:   *N*,*N*-dimethylformamide

dNTPs

:   deoxyribonucleotides

EPL

:   expressed protein ligation

Fmoc

:   9-fluorenylmethyloxycarbonyl group

IPTG

:   isopropyl-β-[d]{.smallcaps}-thiogalactopyranoside

LB

:   Luria-Bertani

MESNA

:   2-mercaptoethane sulfonate

NCL

:   native chemical ligation

TE

:   Tris--EDTA
